Achieve Life Sciences (NASDAQ:ACHV) Share Price Passes Above 200-Day Moving Average – What’s Next?

Posted by Stanley Muller on Sep 19th, 2026

Achieve Life Sciences, Inc. (NASDAQ:ACHV – Get Free Report) shares passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $5.54 and traded as high as $8.11. Achieve Life Sciences shares last traded at $7.91, with a volume of 1,871,086 shares.

Analysts Set New Price Targets

ACHV has been the subject of a number of recent research reports. Raymond James Financial reissued a “strong-buy” rating and set a $18.00 price target on shares of Achieve Life Sciences in a research report on Wednesday, August 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Achieve Life Sciences in a research report on Wednesday, August 19th. UBS Group reaffirmed a “buy” rating on shares of Achieve Life Sciences in a research report on Wednesday, August 12th. Morgan Stanley started coverage on shares of Achieve Life Sciences in a research note on Thursday, August 13th. They issued an “overweight” rating and a $13.00 price objective on the stock. Finally, Wall Street Zen downgraded Achieve Life Sciences from a “hold” rating to a “strong sell” rating in a research report on Saturday, August 15th. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Achieve Life Sciences has an average rating of “Buy” and an average target price of $15.00.

View Our Latest Analysis on Achieve Life Sciences

Achieve Life Sciences Stock Performance

The company has a market capitalization of $821.14 million, a PE ratio of -5.15 and a beta of 2.25. The firm’s 50-day simple moving average is $7.18 and its 200-day simple moving average is $5.55. The company has a current ratio of 0.95, a quick ratio of 0.95 and a debt-to-equity ratio of 0.87.

Achieve Life Sciences (NASDAQ:ACHV – Get Free Report) last issued its earnings results on Tuesday, August 11th. The biopharmaceutical company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.64). On average, research analysts predict that Achieve Life Sciences, Inc. will post -0.91 earnings per share for the current year.

Insider Buying and Selling

In other Achieve Life Sciences news, Director Richard Stewart sold 20,626 shares of the company’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $8.49, for a total transaction of $175,114.74. Following the completion of the sale, the director owned 208,249 shares in the company, valued at $1,768,034.01. This represents a 9.01% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 1.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. WINTON GROUP Ltd purchased a new stake in Achieve Life Sciences in the second quarter valued at about $278,000. Frazier Life Sciences Management L.P. acquired a new position in Achieve Life Sciences in the 2nd quarter worth approximately $49,725,000. AXQ Capital LP raised its holdings in shares of Achieve Life Sciences by 65.6% during the second quarter. AXQ Capital LP now owns 25,173 shares of the biopharmaceutical company’s stock worth $164,000 after purchasing an additional 9,972 shares during the last quarter. Alyeska Investment Group L.P. acquired a new position in shares of Achieve Life Sciences in the 2nd quarter valued at about $12,575,000. Finally, Wellington Management Group LLP acquired a new position in Achieve Life Sciences in the second quarter valued at approximately $9,318,000. Hedge funds and other institutional investors own 33.52% of the company’s stock.

About Achieve Life Sciences

(Get Free Report)

Achieve Life Sciences, Inc is a clinical-stage pharmaceutical company focused on developing and commercializing cytisinicline, an investigational therapy designed to help adults stop smoking and address nicotine dependence. The company is listed on the Nasdaq Capital Market under the symbol ACHV.

Cytisinicline is a plant-derived small molecule that acts on neuronal nicotinic acetylcholine receptors involved in nicotine addiction. Achieve is evaluating the therapy in clinical studies for smoking cessation and potential support for quitting other forms of nicotine use.